(Q35009729)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

Update on Hsp90 inhibitors in clinical trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

6

L Neckers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

7

J B Trepel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Y S Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S V Alarcon

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Lee

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M-J Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

Current Topics in Medicinal Chemistry

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1479-1492

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone

11 February 2020

cites work

1 reference

12 December 2020

90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

1 reference

12 December 2020

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition

1 reference

12 December 2020

Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors

1 reference

12 December 2020

A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer

1 reference

12 December 2020

Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1

1 reference

12 December 2020

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study

1 reference

12 December 2020

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma.

1 reference

12 December 2020

A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.

1 reference

12 December 2020

Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous hsp90 inhibition by geldanamycin and proteasome inhibition by velcade

1 reference

12 December 2020

A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies

1 reference

12 December 2020

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

1 reference

12 December 2020

[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.

1 reference

12 December 2020

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

1 reference

12 December 2020

Pharmacodynamic-guided modified continuous reassessment method-based, dose-finding study of rapamycin in adult patients with solid tumors

1 reference

12 December 2020

Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition

1 reference

12 December 2020

Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation

1 reference

12 December 2020

Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors

1 reference

12 December 2020

A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study

1 reference

12 December 2020

Heat shock protein 90 as a drug target: some like it hot.

1 reference

12 December 2020

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

12 December 2020

Natural Product Origins of Hsp90 Inhibitors

1 reference

12 December 2020

Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and

1 reference

12 December 2020

Antimyeloma activity of heat shock protein-90 inhibition.

1 reference

12 December 2020

Discovery and development of pyrazole-scaffold Hsp90 inhibitors

1 reference

12 December 2020

A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer

1 reference

12 December 2020

Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Commentary re: P. Münster et al., Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an

1 reference

12 December 2020

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis

1 reference

12 December 2020

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

1 reference

12 December 2020

Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET

1 reference

12 December 2020

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer

1 reference

12 December 2020

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

1 reference

12 December 2020

Targeting Hsp90: small-molecule inhibitors and their clinical development

1 reference

12 December 2020

Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress

1 reference

12 December 2020

Phenotypic change from transformed to normal induced by benzoquinonoid ansamycins accompanies inactivation of p60src in rat kidney cells infected with Rous sarcoma virus

1 reference

12 December 2020

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.

1 reference

12 December 2020

Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity.

1 reference

12 December 2020

Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents.

1 reference

12 December 2020

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

1 reference

12 December 2020

Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive

1 reference

12 December 2020

Discovery and development of purine-scaffold Hsp90 inhibitors

1 reference

12 December 2020

Signalling molecules essential for neuronal survival and differentiation

1 reference

12 December 2020

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

1 reference

12 December 2020

Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel

1 reference

12 December 2020

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

1 reference

12 December 2020

Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study

1 reference

12 December 2020

Discontinued drugs in 2008: oncology drugs

1 reference

12 December 2020

10.2174/156802609789895728

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19860730%20AND%20SRC:MED&resulttype=core&format=json

release_mzpjshcodbf37oushxnpbpbj3a

11 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mzpjshcodbf37oushxnpbpbj3a

24 November 2022

mapped directly with Wikidata item

0 references

1 reference